Compare Biogen Inc (BIIB) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares MSCI South Korea ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares MSCI South Korea ETF trades at $176.06. The key difference: Biogen Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | EWY | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $219.20 |
52-Week Low | $128.93 | $71.22 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
EWY, the iShares MSCI South Korea ETF, trades at $175.87, up 7.82% in 24 hours, with a neutral technical signal overall. Recent news highlights volatility in South Korean equities tied to AI and semiconductor stocks, including government support initiatives and foreign capital outflows. The ETF's technical indicators show mixed signals, with bullish moving averages but neutral oscillators, while support and resistance levels suggest near-term consolidation.
The outlook for EWY hinges on South Korea's semiconductor sector recovery and broader market sentiment. Opportunities include potential rebounds from oversold conditions and government-backed chip investments, but risks involve continued volatility from AI trade unwinds and global macroeconomic pressures. Investor caution is warranted amid mixed analyst views and regulatory scrutiny on leveraged ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
